Literature DB >> 10370374

Correlation of thymic pathology with HLA in myasthenia gravis.

A Machens1, C Löliger, U Pichlmeier, T Emskötter, C Busch, J R Izbicki.   

Abstract

The aim of this study was to investigate associations between thymic pathology and HLA in myasthenia gravis. HLA typing was performed in 95 of 125 Caucasian patients who underwent transsternal thymectomy for myasthenia gravis between 1976 and 1995. Multiple comparison procedures applied within each HLA locus demonstrated significant correlations between the ancestral suprahaplotype A1 B8 DRB1*0301 DRB3*0101 DQA1*0501 and thymic hyperplasia and between HLA-A24 and thymoma. A weaker association was found between A3 and thymic atrophy and thymolipoma. On logistic discriminant analysis, HLA-B8 (P = 0.001) and HLA-A3 (P = 0.028) were identified as the only significant classifiers to jointly provide a good discriminator between the thymic pathologies. When the suitability of HLA for detection of thymoma was examined in a second logistic regression analysis, both HLA-A24 (OR 9.7; 95% CI [1.6, 73.7]) and HLA-B8 (OR 0.1; 95% CI [0.0, 0.5]) were significant predictive factors. The above correlations between thymic pathology and HLA-A3, HLA-A24, and HLA-B8 (but not MHC class II alleles) suggest an involvement of MHC class I restricted T cells in myasthenic autoimmunity that may partially be reflected by thymic pathology.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10370374     DOI: 10.1006/clim.1999.4710

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  8 in total

Review 1.  Thymoma and autoimmunity.

Authors:  Shahar Shelly; Nancy Agmon-Levin; Arie Altman; Yehuda Shoenfeld
Journal:  Cell Mol Immunol       Date:  2011-02-14       Impact factor: 11.530

2.  Thymopoiesis, regulatory T cells, and TCRVbeta expression in thymoma with and without myasthenia gravis, and modulatory effects of steroid therapy.

Authors:  Andrea Fattorossi; Alessandra Battaglia; Alexia Buzzonetti; Giacomo Minicuci; Raffaella Riso; Laura Peri; Giovanni Scambia; Amelia Evoli
Journal:  J Clin Immunol       Date:  2007-11-14       Impact factor: 8.317

3.  Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population.

Authors:  Angelina H Maniaol; Ahmed Elsais; Åslaug R Lorentzen; Jone F Owe; Marte K Viken; Hanne Sæther; Siri T Flåm; Geir Bråthen; Margitta T Kampman; Rune Midgard; Marte Christensen; Anna Rognerud; Emilia Kerty; Nils Erik Gilhus; Chantal M E Tallaksen; Benedicte A Lie; Hanne F Harbo
Journal:  PLoS One       Date:  2012-05-09       Impact factor: 3.240

4.  Human Leucocyte Antigen B50 Is Associated with Conversion to Generalized Myasthenia Gravis in Patients with Pure Ocular Onset.

Authors:  Bedile Irem Tiftikcioglu; Irem Fatma Uludag; Yasar Zorlu; İbrahim Pirim; Ufuk Sener; Figen Tokucoglu; Meltem Korucuk
Journal:  Med Princ Pract       Date:  2016-10-31       Impact factor: 1.927

Review 5.  Associations between HLA and autoimmune neurological diseases with autoantibodies.

Authors:  Sergio Muñiz-Castrillo; Alberto Vogrig; Jérôme Honnorat
Journal:  Auto Immun Highlights       Date:  2020-01-22

6.  Myasthenia gravis-specific aberrant neuromuscular gene expression by medullary thymic epithelial cells in thymoma.

Authors:  Yoshiaki Yasumizu; Naganari Ohkura; Hisashi Murata; Makoto Kinoshita; Soichiro Funaki; Satoshi Nojima; Kansuke Kido; Masaharu Kohara; Daisuke Motooka; Daisuke Okuzaki; Shuji Suganami; Eriko Takeuchi; Yamami Nakamura; Yusuke Takeshima; Masaya Arai; Satoru Tada; Meinoshin Okumura; Eiichi Morii; Yasushi Shintani; Shimon Sakaguchi; Tatsusada Okuno; Hideki Mochizuki
Journal:  Nat Commun       Date:  2022-07-22       Impact factor: 17.694

Review 7.  Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC.

Authors:  Luca Cantini; Federica Pecci; Filippo Merloni; Andrea Lanese; Edoardo Lenci; Francesco Paoloni; Joachim G J V Aerts; Rossana Berardi
Journal:  Explor Target Antitumor Ther       Date:  2021-02-28

8.  HLA Class I Allele Frequencies in Southern Iranian Women with Breast Cancer.

Authors:  Mahboobeh Razmkhah; Abbas Ghaderi
Journal:  Iran J Basic Med Sci       Date:  2013-02       Impact factor: 2.699

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.